Compare Aspen Aerogels Inc (ASPN) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Aspen Aerogels Inc vs Merck & Co., Inc. — how do they compare? Aspen Aerogels Inc trades at $6.14 (market cap $509.55M), while Merck & Co., Inc. trades at $132.68 (market cap $321.77B). The key difference: Merck & Co., Inc. is far larger — about 631.5× Aspen Aerogels Inc's market cap, and Merck & Co., Inc. pays a 2.61% dividend while Aspen Aerogels Inc pays none. Which is the better fit depends on your goals.
| ASPN | MRK | |
|---|---|---|
Market Cap | $509.55M | $321.77B |
Sector | Technology | Health |
52-Week High | $8.82 | $132.93 |
52-Week Low | $2.57 | $77.60 |
Enterprise Value | $482.96M | $368.53B |
Dividend Yield | — | 2.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ASPN trades at $6.15, down 2.23% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue beat but missed EPS estimates, with a net income margin of -62.45% and negative cash flow. Recent news highlights sequential revenue improvement and a raised European Thermal Barrier outlook for 2026.
Outlook hinges on execution of Q3 revenue guidance of $65-80M and adjusted EBITDA of $7-15M. Risks include persistent losses and competitive pressures, but analyst consensus is strongly bullish with 82.61% buy ratings, suggesting confidence in the recovery trajectory.
Merck (MRK) trades at $130.45, down 0.34% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.27. Revenue for 2025 reached $65.01B, net income was $18.25B, and the P/E ratio stands at 104.34. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives.
Outlook: Merck's acquisition strategy and consistent dividend payments ($0.85 per share) support a positive view, with analyst consensus price target at $140.58. Risks include high valuation multiples and competitive pressures in pharmaceuticals. Institutional holdings show increased interest, but investors should monitor integration of acquisitions and patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Aspen Aerogels Inc
Aspen Aerogels is an aerogel technology company that designs high-performance insulation. Its products are used in energy infrastructure and electric vehicles to provide thermal management and fire protection.
Read more on ASPN →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
